89bio (ETNB) Earnings Date & Reports

Get AI intraday signals

A.I. Advisor

published Earnings

ETNB is expected to report earnings to fall 45.68% to -75 cents per share on March 19

Q4'24

Est.

$-0.75

Q3'24

Missed

by $0.77

Q2'24

Beat

by $0.08

Q1'24

Missed

by $0.08

Q4'23

Missed

by $0.01

The last earnings report on November 08 showed earnings per share of -138 cents, missing the estimate of -62 cents. With 4.50M shares outstanding, the current market capitalization sits at 932.43M.

View a ticker or compare two or three

Compare

ETNB

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For ETNB
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for ETNB (Try 14 days for Free)

A.I. Advisor

published General Information

General Information

a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

142 Sansome Street

Phone

+1 415 432-9270

Employees

Web

https://www.89bio.com